Literature DB >> 15319205

Differing effects of epinephrine, norepinephrine, and vasopressin on survival in a canine model of septic shock.

Peter C Minneci1, Katherine J Deans, Steven M Banks, Renee Costello, Gyorgy Csako, Peter Q Eichacker, Robert L Danner, Charles Natanson, Steven B Solomon.   

Abstract

During sepsis, limited data on the survival effects of vasopressors are available to guide therapy. Therefore, we compared the effects of three vasopressors on survival in a canine septic shock model. Seventy-eight awake dogs infected with differing doses of intraperitoneal Escherichia coli to produce increasing mortality were randomized to receive epinephrine (0.2, 0.8, or 2.0 microg.kg(-1).min(-1)), norepinephrine (0.2, 1.0, or 2.0 microg.kg(-1).min(-1)), vasopressin (0.01 or 0.04 U/min), or placebo in addition to antibiotics and fluids. Serial hemodynamic and biochemical variables were measured. Increasing doses of bacteria caused progressively greater decreases in survival (P <0.06), mean arterial pressure (MAP) (P <0.05), cardiac index (CI) (P <0.02), and ejection fraction (EF) (P=0.02). The effects of epinephrine on survival were significantly different from those of norepinephrine and vasopressin (P=0.03). Epinephrine had a harmful effect on survival that was significantly related to drug dose (P=0.02) but not bacterial dose. Norepinephrine and vasopressin had beneficial effects on survival that were similar at all drug and bacteria doses. Compared with concurrent infected controls, epinephrine caused greater decreases in CI, EF, and pH, and greater increases in systemic vascular resistance and serum creatinine than norepinephrine and vasopressin. These epinephrine-induced changes were significantly related to the dose of epinephrine administered. In this study, the effects of vasopressors were independent of severity of infection but dependent on the type and dose of vasopressor used. Epinephrine adversely affected organ function, systemic perfusion, and survival compared with norepinephrine and vasopressin. In the ranges studied, norepinephrine and vasopressin have more favorable risk-benefit profiles than epinephrine during sepsis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15319205     DOI: 10.1152/ajpheart.00450.2004

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  6 in total

1.  Noradrenaline in preterm infants with cardiovascular compromise.

Authors:  Kirsten Rowcliff; Koert de Waal; Abdel-Latif Mohamed; Tejasvi Chaudhari
Journal:  Eur J Pediatr       Date:  2016-10-15       Impact factor: 3.183

2.  Antibacterial effects of lidocaine and adrenaline.

Authors:  Sevgi Kesici; Mehmet Demirci; Ugur Kesici
Journal:  Int Wound J       Date:  2019-08-12       Impact factor: 3.315

3.  Effects of intra-aortic balloon counterpulsation in a model of septic shock.

Authors:  Steven B Solomon; Peter C Minneci; Katherine J Deans; Jing Feng; Peter Q Eichacker; Steven M Banks; Robert L Danner; Charles Natanson; Michael A Solomon
Journal:  Crit Care Med       Date:  2009-01       Impact factor: 7.598

4.  Effects of dexmedetomidine and esmolol on systemic hemodynamics and exogenous lactate clearance in early experimental septic shock.

Authors:  Glenn Hernández; Pablo Tapia; Leyla Alegría; Dagoberto Soto; Cecilia Luengo; Jussara Gomez; Nicolas Jarufe; Pablo Achurra; Rolando Rebolledo; Alejandro Bruhn; Ricardo Castro; Eduardo Kattan; Gustavo Ospina-Tascón; Jan Bakker
Journal:  Crit Care       Date:  2016-08-02       Impact factor: 9.097

5.  Norepinephrine supplemented with dobutamine or epinephrine for the cardiovascular support of patients with septic shock.

Authors:  Khaled M Mahmoud; Amany S Ammar
Journal:  Indian J Crit Care Med       Date:  2012-04

6.  Severe hyperlactatemia with normal base excess: a quantitative analysis using conventional and Stewart approaches.

Authors:  Graciela Tuhay; María Carolina Pein; Fabio Daniel Masevicius; Daniela Olmos Kutscherauer; Arnaldo Dubin
Journal:  Crit Care       Date:  2008-05-08       Impact factor: 9.097

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.